When it comes to investing in companies with exposure to the rapidly evolving early cancer detection/screening market, the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) stands above the rest. Part of the early cancer screening equation is liquid biopsies, a niche some ARKG components...